Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
==== Serious illness ==== Serious illness may result in low blood sugar. Severe disease of many organ systems can cause hypoglycemia as a secondary problem. Hypoglycemia is especially common in those in the intensive care unit or those in whom food and drink is withheld as a part of their treatment plan. Sepsis, a common cause of hypoglycemia in serious illness, can lead to hypoglycemia through many ways. In a state of sepsis, the body uses large amounts of glucose for energy. Glucose use is further increased by cytokine production. Cytokines are a protein produced by the body in a state of stress, particularly when fighting an infection. Cytokines may inhibit glucose production, further decreasing the body's energy stores. Finally, the liver and kidneys are sites of glucose production, and in a state of sepsis those organs may not receive enough oxygen, leading to decreased glucose production due to organ damage. Other causes of serious illness that may cause hypoglycemia include liver failure and kidney failure. The liver is the main site of glucose production in the body, and any liver failure or damage will lead to decreased glucose production. While the kidneys are also sites of glucose production, their failure of glucose production is not significant enough to cause hypoglycemia. Instead, the kidneys are responsible for removing insulin from the body, and when this function is impaired in kidney failure, the insulin stays in circulation longer, leading to hypoglycemia.
=== Conservation and sustainability === E. longifolia is mainly used for its roots, which necessitates uprooting the entire plant when it is harvested. This has led to concerns over the long-term sustainability of its use. In Malaysia raw E. longifolia is banned from export, and the plant itself been listed as one of the priority species for conservation, and the harvesting of wild trees is restricted according to Act 686 on International Trade in Endangered Species. In 2016, Ahmad Shabery Cheek, the Malaysian Minister of Agriculture, said that the species may go extinct within twenty years if cultivation and replanting efforts are not made quickly. To support commercialization, the Malaysian government made attempts to encourage the long-term commercial cultivation of the plant, through the provision of grants for farmers, enabling agronomy research by MARDI, and the formation of cluster farms under the East Coast Economic Region.
A level of <70 mg/dL (<3.8 mmol/L) is described as a hypoglycemic attack (low blood sugar). Most diabetics know when they are hypoglycemic and seek food or a sweet drink to raise their glucose levels. Intensive efforts to achieve blood sugar levels close to normal have been shown to triple the risk of the most severe form of hypoglycemia, in which the person requires assistance from by-standers in order to treat the episode. Among intensively controlled type 1 diabetics, 55% of episodes of severe hypoglycemia occur during sleep, and 6% of all deaths in diabetics under the age of 40 are from hypoglycemia at night. Hypoglycemia can be problematic if it occurs while driving as it can affect a person's thinking process, coordination, and state of consciousness. Some people are more prone to hypoglycemia as they have reported fewer warning symptoms, and their body released less epinephrine (a hormone that helps raise blood glucose). Additionally, individuals with a history of hypoglycemia-related driving mishaps appear to use sugar at a faster rate. Drivers with diabetes susceptible to driving mishaps should monitor their blood sugar to be not less than 70 mg/dL (3.9 mmol/L). Instead, these drivers are advised to treat hypoglycemia and delay driving until their blood glucose is above 90 mg/dL (5 mmol/L).
Sources: en.wikipedia.org
college sports) SOD (i/a) School Of Dentistry Statement Of Difference(s) Statement Of Direction Statement Of Documentation Statement Of Duty/Duties SOE (i) Secret Of Evermore Special Operations Executive (WWII British organization) State Of Emissions (EW) SOF (a/i) Special Operations Force(s) Status of Forces SOFIA – (a) Stratospheric Observatory For Infrared Astronomy SOGAT (a) Society of Graphical and Allied Trades Former British printing union SOHC – (i) Single-OverHead-Cam engine SOHO – (p) Solar and Heliospheric Observatory SOI (i) Signal Operating Instruction (i) Southern Oscillation Index SOL – (i) Shit Out of Luck SOLIS – (i) Synoptic Optical Long-term Investigations of the Sun som – (s) Somali language (ISO 639-2 code) SOM (a) Simulation Object Model (s) Somalia (ISO 3166 trigram) Sonar – (p) SOund Navigation And Ranging SOP (i) Standing/Standard Operating Procedure State of Play SOR (i) State Of Readiness Statement Of Requirements SOS (s) Somali shilling (ISO 4217 currency code) Save Our Souls SOSTAR – (a) Stand-Off Surveillance and Target Acquisition Radar sot – (s) Sotho language (ISO 639-2 code) SOUTHAG – (p) Southern Army Group SOUTHCOM – (p) (U.S.) Southern Command SOV – (i) Single Occupant Vehicle SOW – (i) Statement Of Work SOWHAT – (p) RESNA Subcommittee on Wheelchairs and Transportation SOX – (p) Sarbanes–Oxley Act
== Diagnosis == SJIA is diagnosed clinically and corroborated by typical test findings; it is a diagnosis of exclusion. Other causes of fever, such as infections, cancer, and other inflammatory/rheumatologic disorders such autoinflamatory syndromes, systemic lupus erythematosus, and Kawasaki disease, must be ruled out. When a child is suspected of having sJIA, they should always have a full evaluation for infection and cancer. This evaluation should include blood and urine cultures, imaging tests, and perhaps a bone marrow exam or lymph node biopsy to rule out leukemia or lymphoma. According to the most recent International League of Associations for Rheumatology (ILAR) criteria, a child must have arthritis, ≥2 weeks of daily fever that is documented as occurring daily for ≥3 days, and any one of the following symptoms to be classified as having sJIA: organomegaly, lymphadenopathy, serositis, or non-fixed/evanescent rash While there are typical patterns of laboratory abnormalities, such as elevated C-reactive protein levels, high erythrocyte sedimentation rates, neutrophilia, thrombocytosis, and microcytic anemia, there are no particular laboratory tests for sJIA.
Valve announced Episode Three in May 2006, planning to release it by Christmas 2007. Concept art appeared in 2007. Valve released little information in the following years, with no clarity on whether further Half-Life games were coming. In 2011, Wired described Episode Three as vaporware. In 2017, Business Insider described it as "the world's most anticipated game", but said that it had become a "farce". Valve eventually canceled Episode Three and abandoned episodic development, as they wanted to create more ambitious games. According to the level designer Dario Casali, "We found ourselves creeping ever forward towards, 'Well, let's just keep putting more and more, and more, and more stuff in this game because we want to make it as good as we can,' and then we realized these episodes are turning more into sequels." The team became fatigued with Half-Life and struggled to discover new gameplay mechanics. The designer Robin Walker said Valve used Half-Life games to "solve some interesting collision of technology and art that had reared itself". Working on Episode Three, they failed to find a unifying idea that provided a sense of "wonderment, or opening, or expansion". Additionally, Valve had started developing a new game engine, Source 2. As developing Half-Life 2 and the original Source engine simultaneously had created problems, Valve delayed development of a new Half-Life until Source 2 was complete. After completing other projects, such as the multiplayer game Left 4 Dead (2008), the team felt the opportunity to create Episode Three had passed.
===== Alkenones ===== Another group of molecules often used in paleoreconstructions are alkenones, long-chain largely unsaturated lipids produced exclusively by coccolithophores. Coccolithophores are marine haptophyte algae, and include the globally iconic species Emiliania huxleyi, one of the main CaCO3 producers in the ocean. The δDs of alkenones are highly correlated to the δDs of seawater, and so can be used to reconstruct paleoenvironmental properties that constrain the isotopic composition of sea water. The most notable reconstruction that alkenone δD values are applied to is the salinity of ancient oceans.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.